BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to
metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with
insufficient glycaemic control.